The asssessment of the efficacy of induction radiochemotherapy using low doses of ionizing radiation (iCHRTL) in the treatment of patients with advanced throat and larynx cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517480-23-00

Acronym

iCHRTL/2021

Enrollment

Registered

2024-12-09

Start date

2022-02-17

Completion date

Unknown

Last updated

2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced throat and larynx cancer

Brief summary

Objective response rate after induction assessment (ORR), Local and nodal healing rate assessement (LRC), Assessment of iCHRTL tolerance in patients with advanced cancer of the throat or larynx - the frequency of side effects by system

Detailed description

Distant metastases rate assessment, Overall survival assessment, Evaluation of the molecular and biochemical effect of low doses of ionizing radiation, Relapse free survival (RFS) assessment, Progression free survival (PFS) assessment

Interventions

DRUGPaclitaxel Kabi

DRUG6 mg/ml

DRUGkoncentrat do sporządzania roztworu do infuzji

DRUGCarboplatin Pfizer

DRUG10 mg/ml

DRUGroztwór do wstrzykiwań

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate after induction assessment (ORR), Local and nodal healing rate assessement (LRC), Assessment of iCHRTL tolerance in patients with advanced cancer of the throat or larynx - the frequency of side effects by system	—

Secondary

Measure	Time frame
Distant metastases rate assessment, Overall survival assessment, Evaluation of the molecular and biochemical effect of low doses of ionizing radiation, Relapse free survival (RFS) assessment, Progression free survival (PFS) assessment	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026